Intuitive Surgical (ISRG)
(Delayed Data from NSDQ)
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
Pre-Market: $482.00 -4.62 (-0.95%) 9:24 AM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
Pre-Market: $482.00 -4.62 (-0.95%) 9:24 AM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
Intuitive Surgical (ISRG) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Intuitive Surgical (ISRG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stock Market News For Mar 18, 2019
by Zacks Equity Research
Markets closed in the green on Friday as optimism around a U.S. - China trade deal boosted investor sentiment.
Intuitive Surgical da Vinci SP Gets FDA Nod, Prospects Bright
by Zacks Equity Research
Intuitive Surgical (ISRG) fortifies its foothold in the global robotic-surgery market.
Intuitive Surgical (ISRG) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Intuitive Surgical (ISRG) closed at $558.29 in the latest trading session, marking a -0.08% move from the prior day.
RTI Surgical Buys Paradigm Spine, Adds Coflex to Portfolio
by Zacks Equity Research
RTI Surgical's (RTIX) acquisition of Paradigm Spine aligns with the former's goal of expanding its spine portfolio.
Top Stock Reports for Visa, Honeywell & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa (V), Honeywell (HON) and Biogen (BIIB).
Intuitive Surgical (ISRG) Up 2.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intuitive Surgical (ISRG) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Intuitive Surgical (ISRG) closed at $549.87, marking a +0.04% move from the previous day.
Intuitive Surgical Gets FDA Nod for Ion Endoluminal System
by Zacks Equity Research
The regulatory go-ahead for the Ion platform is likely to provide Intuitive Surgical (ISRG) a competitive edge in the minimally-invasive-care space.
Here's Why You Should Hold Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical's (ISRG) solid exposure to robotics & medical mechatronics is commendable. Its robot-based da Vinci Surgical System for minimally-invasive surgery is an added positive.
Top Stock Reports for United Technologies, Lockheed Martin & NextEra Energy
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including United Technologies (UTX), Lockheed Martin (LMT) and NextEra Energy (NEE).
Intuitive Surgical (ISRG) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Intuitive Surgical (ISRG) closed at $494.25 in the latest trading session, marking a -0.5% move from the prior day.
Accuray & China Isotope Collaborate to Sell Radiation Devices
by Zacks Equity Research
Management at Accuray (ARAY) sees bright prospects in China.
Has Intuitive Surgical (ISRG) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ISRG) Outperforming Other Medical Stocks This Year?
Stock Market News for Jan 25, 2019
by Zacks Equity Research
Wall Street ended mixed on Thursday after investors received strong earnings numbers amidst lingering concerns over trade negotiations.
Intuitive Surgical (ISRG) Earnings Miss, Revenues Beat in Q4
by Zacks Equity Research
Solid show by flagship da Vinci system drives Intuitive Surgical's (ISRG) Q4 results.
The Zacks Analyst Blog Highlights: Intel, Starbucks, Intuitive Surgical and Western Digital
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intel, Starbucks, Intuitive Surgical and Western Digital
Post-Bell Q4 Highlights: Intel, Starbucks & More
by Mark Vickery
We see a fresh new crop of Q4 earnings reports hitting the tape, with INTC and SBUX leading the way.
Will Flagship Impella Drive ABIOMED's (ABMD) Q3 Earnings?
by Zacks Equity Research
ABIOMED (ABMD) is likely to gain from flagship Impella in third-quarter fiscal 2019; positive trends in the CHD markets buoy optimism.
Will Core Renal Care Unit Fuel Baxter's (BAX) Q4 Earnings?
by Zacks Equity Research
Management at Baxter (BAX) expects Renal Care to see growth of 3-4% in 2018.
Can Diagnostic Revenues Fuel PerkinElmer's (PKI) Q4 Earnings?
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter 2018 results are likely to benefit from the Diagnostics Segment's solid performance.
Accuray's (ARAY) Q2 Loss Narrows, Radixact Demand Shoots Up
by Zacks Equity Research
Demand for flagship Radixact & CyberKnife platforms aids Accuray's (ARAY) fiscal Q2 results.
Why Earnings Season Could Be Great for Intuitive Surgical (ISRG)
by Zacks Equity Research
Intuitive Surgical (ISRG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
CONMED (CNMD) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
CONMED's (CNMD) Q4 results get a boost from solid segmental performances.
ISRG, RMD Earnings on Jan 24: Here Are the Key Predictions
by Zacks Equity Research
Let's take a look at the factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical space.